Before scheduling your appointment, we recommend you contact your insurance company to verify that the OHSU Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any copayments, co–insurance, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with OHSU providers, your out of pocket liability may be higher. Visit the billing and insurance section of our site for more information.
Dr. Swords received his medical degree from the National University of Ireland, Galway, in 2000. He completed fellowship training in hematology with the Royal College of Pathology, London (2008). He then pursed additional fellowship training in experimental therapeutics at the University of Texas Health Science Center San Antonio, followed by his PhD thesis which focused on post translational modification pathways in AML. In 2012, he joined the University of Miami to lead the adult leukemia program at that institution. In 2018, he moved to AbbVie Pharmaceuticals as a medical director, where he supported the development of venetoclax in myeloid malignancies.
Dr. Swords is a fellow of the Royal College of Physicians of Ireland (FRCPI) and the Royal College of Pathologists London (FRCPath). He has published over 150 peer reviewed manuscripts and abstracts in the area of myeloid neoplasia and thematically, his publications focus on translational science and early phase clinical trials for these diseases. He has given oral presentations at local and international meetings including the American Society of Hematology (ASH) and the European Hematology Association (EHA) relating to AML therapeutics. He also serves as an editor for Leukemia Research Reports as well as a manuscript reviewer for a number of high impact factor journals including Blood and Leukemia. He has received funding from private foundations, pharma, and the NCI, to conduct investigator initiated projects in his field of investigation.
Dr. Swords has always been fascinated by hematology as a medical specialty. The unique integration between the laboratory and the clinic was a key factor in his decision to be a hematologist. Currently, he specializes in treating patients with blood cancers. The main goal of his research is to develop better drugs for patients with leukemia and related diseases. As a native Irishman, he enjoys going home to visit his family and friends. In his spare time, he likes to read and play piano (fun fact: he supported himself through medical school by teaching kids to play piano!).
- M.D., 2000, National University of Ireland, Galway (NUIG)
- Ph.D., 2012, National University of Ireland, Galway (NUIG)
- General Internal Medicine, Royal College of Physicians of Ireland (RCPI), 2002, (MRCPI)
- Hematology, Royal College of Pathologists, London, UK (FRCPath), 2008
- Experimental Therapeutics, University of Texas Health Science Center, San Antonio (UTHSCSA), 2009
- General Internal Medicine, Royal College of Physicians of Ireland (FRCPI), 2011
- General Internal Medicine, RCPI, 2002
- Hematology, FRCPath, 2008
Memberships and associations
- Royal College of Physicians of Ireland (RCPI), member, November 2002
- Royal College of Physicians of Ireland (RCPI), fellow, November 2011
- Royal College of Pathologists London UK (RCPath), fellow, November 2007
- Haematology Association of Ireland (HAI), member, December 2003
- American Society of Hematology (ASH), member, November 2010
- South West Oncology Group (SWOG), member, March 2009
- American Society of Clinical Oncology (ASCO), member, April 2010
- Developmental Therapeutics Consortium (DTC), member, June 2010